USA – Cytovance Biologics has announced a strategic collaboration with fellow CDMO Alcami Corporation to amplify its extensive large molecule biologic manufacturing and sterile fill-finish capabilities.
At the forefront of conquering development and manufacturing hurdles, Cytovance refines distinctive processes crucial for propelling drug developers towards pivotal milestones.
Axel Schleyer, Cytovance’s Chief Commercial Officer, expressed enthusiasm about merging Alcami’s proficiency in liquid and lyophilization sterile filling, packaging, and labeling with Cytovance’s bulk drug substance development and manufacturing services.
Schleyer emphasized the synergistic cultures of quality and innovation, identifying this partnership as instrumental in bolstering life-altering drugs through every phase, from early development to commercial supply.
Amidst the surge in potential drug targets, numerous developers lacking internal manufacturing capabilities struggle on their journey to clinical trials.
This predicament demands adept CDMO partners to facilitate future commercialization aspirations.
Effectively bringing challenging-to-express and complex-to-produce products to market hinges on collaborating with seasoned experts boasting years of experience.
This expertise facilitates the transformation of selected molecules into bulk drug substances, ultimately reaching patients in need.
Alcami’s inclusion of sterile fill-finish spaces and state-of-the-art manufacturing and filling lines enriches Cytovance’s offerings.
This enhancement provides customers the opportunity to seamlessly transition their bulk products to a reputable cGMP partner for advanced clinical and commercial production and packaging.
Alcami’s comprehensive suite encompasses formulation, release, stability testing, vial and syringe filling, and advanced cGMP biostorage options, culminating in the successful launch of over 50 commercial products.
Both entities are actively collaborating to synchronize manufacturing processes and quality systems. William Humphries, CEO of Alcami, underscored their commitment to delivering unparalleled expertise in high-quality fill-finish operations.
He highlighted their combined 77 years of serving the life science industry as a testament to their dedication to pharmacological product quality and expediting the delivery of new drug products to patients.
This collaboration with Alcami marks Cytovance’s third publicly acknowledged partnership this year, following two international collaborations with custom microbial strain development providers.
Earlier this year, Alcami announced the implementation of an integrated line concept from Syntegon Technology. This concept allows for increased flexibility and scale in vial filling processes, as it combines liquid filling and lyophilization technology.
The integrated line concept from Syntegon enables Alcami to streamline its vial filling operations by integrating liquid filling and lyophilization processes into a single line.
This integration eliminates the need for multiple lines and reduces the time and resources required for vial filling.
For all the latest packaging and printing industry news from Africa and the World, subscribe to our NEWSLETTER, follow us on Twitter and LinkedIn, like us on Facebook, and subscribe to our YouTube channel.
